文献速递头颈部肿瘤放疗

鼻咽癌选择性淋巴结照射剂量降至45Gy的五年结局大样本研究

De-escalating elective nodal irradiation dose to 45 Gy in nasopharyngeal carcinoma: A large-cohort study with 5-year outcomes.
PubMed 文献 · Radiother Oncol · 2026-09-25

该研究纳入752例接受IMRT并接受45Gy EQD2选择性淋巴结照射的初诊非转移性鼻咽癌患者,中位随访68个月,5年区域控制率97.3%、总生存率89.7%。45Gy计划较50Gy计划显著降低危及器官剂量及主要毒性NTCP,支持进一步前瞻性评估该降剂量策略。

要点

  • 45Gy EQD2选择性淋巴结照射5年区域控制率达97.3%,疗效良好。
  • 45Gy计划较50Gy计划显著降低所有相关危及器官剂量(P<0.001)。
  • 腮腺功能损伤、吞咽困难及甲状腺功能减退的NTCP显著降低(均P<0.001)。

核心结论

  • 45Gy EQD2选择性淋巴结照射剂量可获得良好的长期疗效,同时危及器官保护更优、NTCP降低,支持进一步前瞻性评估该降剂量策略。

研究设计与样本

  • 回顾性大样本队列研究,筛选在本机构接受IMRT并接受45Gy EQD2选择性淋巴结照射的初诊非转移性鼻咽癌患者。
  • 共纳入752例患者,中位随访68个月,评估区域控制、总生存、局部控制和远处控制。
  • 对20例随机选取的病例以相同靶区和危及器官约束重新计划,比较45Gy与50Gy EQD2计划的剂量学差异,并推导主要毒性的NTCP率。

主要发现

  • 5年区域控制率97.3%、局部控制率96.1%、远处控制率90.6%、总生存率89.7%。
  • 23例患者出现区域复发,其中14例位于淋巴结临床靶体积内,包括11例原位淋巴结大体靶体积复发和5例(0.7%)45Gy体积内孤立失败。
  • 与50Gy EQD2计划相比,45Gy EQD2计划显著降低所有相关危及器官剂量(P<0.001)。
  • 腮腺功能损伤、吞咽困难和甲状腺功能减退的中位NTCP显著降低(均P<0.001)。

关键数值与推荐

  • 选择性淋巴结照射剂量为45Gy EQD2(2Gy分次)。
  • 5年区域控制率97.3%、局部控制率96.1%、远处控制率90.6%、总生存率89.7%。
  • 45Gy体积内孤立失败率为0.7%。
  • 45Gy较50Gy EQD2计划降低危及器官剂量P<0.001,降低腮腺功能损伤、吞咽困难及甲状腺功能减退NTCP均P<0.001。

临床怎么用

  • 对于接受IMRT的初诊非转移性鼻咽癌患者,可考虑将选择性淋巴结照射剂量降至45Gy EQD2以改善危及器官保护。
  • 该降剂量策略的长期疗效数据支持在临床研究中进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although recent guidelinesrecommend de-escalatedelective nodal irradiation (ENI) for nasopharyngeal carcinoma (NPC), the optimal dose remains undefined (45-52.6 Gy dose in 2 Gy fractions, EQD2). Weevaluated the long-term efficacy of 45-Gy EQD2 ENI dose in a real-world cohortto inform dose optimization and guideline refinement. MATERIALS AND METHODS: Newly diagnosed, non-metastatic NPC patients treated with intensity-modulated radiotherapy (IMRT) and received 45-Gy EQD2 ENI dose at our institution were screened. Regional control (RC), overall survival (OS), local control (LC), and distant control (DC)were evaluated. Dosimetric comparisons between 45-Gy and 50-Gy EQD2 plans were performed on 20 randomly selected replanned cases using identical target volumes and organs at risk (OARs) constraints. Normal tissue complication probability (NTCP) rates for major toxicities were derived to predict clinical benefit. RESULTS: Totally,752 patients were included. With a median follow-up of 68 months, the 5-year RC, LC, DC, and OS rates were 97.3 %, 96.1 %, 90.6 %, and 89.7 %, respectively. Regional recurrence occurred in 23 patients; 14 were within the nodal clinical target volume, including 11 in-situ nodal gross target volume relapses and five isolated failures (0.7 %) within the 45-Gy volume. The 45-Gy EQD2 plan significantly reduced dose to all relevant OARs (P < 0.001) compared with 50-Gy EQD2 plan. Significant median NTCP reductions were observed for parotid gland function loss, dysphagia and hypothyroidism (all P < 0.001). CONCLUSION: A 45-Gy EQD2 ENI dose provides favorable long-termefficacywith superior OAR sparing and reduced NTCP, supporting further prospective evaluation of this de-escalation strategy in NPC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen X, Huang Y, Lin K, et al. De-escalating elective nodal irradiation dose to 45 Gy in nasopharyngeal carcinoma: A large-cohort study with 5-year outcomes. Radiother Oncol. 2026. PMID: 42790787. doi:10.1016/j.radonc.2026.111795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。